The USC Incubator accelerates the development of USC’s top student and alumni entrepreneurs through experiential education, mentorship and community. The USC Incubator, supported by the Greif Center for Entrepreneurial Studies at USC’s Marshall School takes founders from feasibility and development work, on to customers, a tested business model, getting distribution, building a team, bootstrapping and investment preparation. They also provide access to other supporting resources, such as legal and financial assistance.

23andMe is a human genome research company enabling users to study their ancestry, genealogy, and inherited traits. A startup co-founded by Linda Avey and Anne Wojcicki, the wife of Google co-founder Sergey Brin, 23andMe has plans to make the human genome searchable. Brin, along with Google, gave 23andMe $3.9 million as part of a series A in May of 2007. The company was named after the number of chromosome pairs in humans. They aim to help people understand what their genes mean by indexing them and highlighting significant findings. 23andMe allows its clients/users to study their ancestry, genealogy and inherited traits. The company also markets to researchers and scientists, for whom they provide neatly categorized and easily searchable data. One reason the Google investment in 23andMe made sense was that this company could enable the search giant to index another facet of the world's information. With the Biotech and Health Care industries growing rapidly, 23andMe could help Google get and maintain a market hold in these already multi-billion dollar areas.

Credentis is a Swiss company that develops and commercializes an enamel and dentin demineralization system for the treatment of caries lesions and related illnesses. It aims to provide dentists with a tool in tooth demineralization and help patients protect and regenerate their teeth. The company’s products include Curodont Repair, Curodont Protect, and Curodont D’Senz. Credentis was founded in 2010 and is based in Windisch, Aargau.

two quirky scientists vowed to make the world a better place. After learning their trades in some of the world’s biggest scientific organisations, Paul and Mark Davis (father and son team with a striking resemblance to Pinky and the Brain established Mologic to do as much good as possible in healthcare and education. They want to improve patient care and quality of life, and break new ground in exciting fields of research (unlike Pinky and the Brain who wanted to take over the world).

NeuroTherm, Inc. develops and manufactures products for the treatment of chronic pain. The company offers radiofrequency (RF) generators, RF electrodes, RF cannula, intradiscal therapies, discography systems, and epidural catheters. The company was founded in 2005 and is headquartered in Abbott Park, IL.

Expand Networks is a technology company that helped pioneer the Wide Area Network (WAN) Optimization market. Founded in 1998, Expand Networks has grown to be the leading provider of 'Virtual Proximity' solutions over the Wide Area Network.\nVirtual Proximity' is the experience Expand delivers to users of business critical applications and services across enterprise Wide Area Networks.\nExpand bridges the 'Proximity Gap' by delivering a 'virtual proximity' experience to users. Whether it be server virtualization at the datacenter, server consolidation at the branch office or desktop virtualization for remote users, Expand effectively bridges the 'Proximity Gap' by putting the user in virtual proximity to the application and data centre services.\nExpand Networks 'Virtual Proximity' Experience is available globally via its Network of Expand Certified Resellers, System Integrators, MSPs & OEM Partners.

Bioinfra Co., Ltd. is engaged in the business of research and development of medicine and chemical substances. The company was founded on May 23, 2007 and is headquartered in Suwon, South Korea.

Sangamo BioSciences is a clinical stage biopharmaceutical company involved in gene therapy that is researching ways of commercializing Zinc finger nucleases which modify a cell's DNA at an exact location thereby correcting or disrupting a specific gene. Sangamo BioSciences' lead therapy, SB-728, is a potential functional cure for HIV/AIDS. SB-728 works by removing some of the immune cells from the patient's blood that HIV attacks. The blood is sent to a lab which applies the SB-728 treatment to the patient's immune cells. The treatment removes the protein gateway on the immune cells that HIV needs to infect. The treated cells are then infused back into the patient whereby they reproduce and take over as HIV attacks and kills the non-treated cells. The treated, resistant cells thereby control the HIV infection and thus cures the patient from opportunistic infections that result from HIV. Recent published data further support the company's ongoing progress which has been described as "a major step toward immunological functional control of HIV."

DSM IP Assets BV, a subsidiary of Koninklijke DSM NV, is a company headquartered in Heerlen, the Netherlands, that develops and produces nutrition, pharmacy & material science products.

Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products, including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

OcuNexus Therapeutics, Inc. develops and commercializes therapeutic products for wound care and tissue repair. The firm offers Nexagon, an oligonucleotide that downregulates the gap junction in tissue repair. Its Nexagon also reduces lesion spread, swelling, inflammation, scarring, and time to wound closure in various tissue types, including the eye, skin, spinal cord, nerve, and brain. The company was founded in 2005 by David Lawrence Becker, Colin C. Green and Bradford J. Duft and is headquartered in San Diego, CA.

ProMedTek, Inc. is a medical device technology company. Its product is Replexa+ which serves as a generating device and disposable applicator. The company was founded in 1988 and is headquartered in Scottsdale, AZ.

Siemens AG is a technology company, which engages in the areas of automation and digitalization in the process and manufacturing industries, infrastructure for buildings and energy systems, mobility solutions for rail transport, and medical technology and digital healthcare services. It operates through the following segments: Digital Industries, Smart Infrastructure, Mobility, Siemens Healthineers, and Siemens Financial Services. The Digital Industries segment offers a product portfolio and system solutions for automation used in discrete and process industries. The Smart Infrastructure segment includes products, systems, solutions, services and software to support a transition from fossil to renewable energy sources. The Mobility segment combines all Siemens businesses in the area of passenger and freight transportation. The Siemens Healthineers segment develops, manufactures, and sells diagnostic and therapeutic products, and services to healthcare providers. The Siemens Financial Services segment focuses on financing solutions for Siemens’ customers as well as other companies in the form of debt and equity investments. The company was founded by Johann Georg Halske and Werner von Siemens on October 12, 1847 and is headquartered in Munich, Germany.

Medix Biochemica Oy Ab develops, produces, and markets monoclonal antibodies, antibody services, and recombinant antigens for in vitro diagnostics industry. It also provides rapid tests for human healthcare. The company was founded in 1985 and is headquartered in Espoo, Finland.

Tecopy GROUP is one of the best filmmakers of Studies, Projects and Technical Assistance in the areas of Civil and Industrial Engineering, and Communication Solutions and Access to Information on the Internet-based Geographic Information Systems (GIS or GIS) . Market Engineering & Consulting in Spain is highly fragmented, highly specialized and is very dynamic. Therefore, market activities are evolving in response to the demand for society. The traditional engineering markets evolve towards other future activities with a greater say in the management of services. Likewise, the market will evolve and Technology Consulting. The companies comprising the Tecopy GROUP, start from a position of privilege as the future of engineering and consulting companies, go through the evolution of traditional engineering towards a more consultative engineering and management, and they, given their activities form a whole, TOTALLY FUTURE. Especially, when his experience, can make the most of the work, given the professionalism of their staff. TWENTY years of excellent work behind us! Therefore, the Tecopy GROUP has decided to take a big step in this direction, and a firm commitment to the professionalization of their companies to ensure continuity and profitability of the same, and the evolution of its services to the demands future of society, to prepare for other activities or traditional activities but evolved into facets of management services

Andes Biotechnologies is a leading nucleic acid-based drug discovery and development company focused on solid tumor cancers. The Company has discovered two novel families of long non-coding RNAs: sense (S-RNA) and antisense (AS-RNA). Both are present in all human cells, are synthesized in the mitochondria and migrate to the nucleus. The proprietary technology developed by Andes Biotechnologies is based on oligonucleotide drugs that target the novel long non-coding regulatory RNAs in tumor cells inducing apoptosis. Andes Biotechnologies has an active investigational new drug (IND) application in the United States and is currently engaged in the clinical development of its lead drug Andes-1537. Andes Biotechnologies is supported by a proven and experienced management team, a robust network of key national and international collaborators in the cancer field, and has an extensive intellectual property portfolio. Andes Biotechnologies was founded in 2008 and is located in Santiago, Chile.